SIA
JSPRW icon

SkyView Investment Advisors’s Japer Therapeutics Warrants JSPRW Stock Holding History

SkyView Investment Advisors’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-302
Closed – – 803
2023
Q1 		$0 Hold
302
– – ﹤0.01% 724
2022
Q4 		$0 Hold
302
– – ﹤0.01% 497
2022
Q3 		$0 Hold
302
– – ﹤0.01% 555
2022
Q2 		$0 Hold
302
– – ﹤0.01% 606
2022
Q1 		$0 Buy
302
+300
+15,000% +$167 ﹤0.01% 610
2021
Q4 		$0 Buy
+2
New +$3 ﹤0.01% 577

Other funds holding JSPRW

CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ZA
Zazove Associates Incline Village, Nevada $1.22B AUM 1.91% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SkyView Investment Advisors's JSPRW Position: Q2 2023 in Review

SkyView Investment Advisors sold out of Japer Therapeutics Warrants (JSPRW) in Q2 2023, closing a stake of 302 shares.

SkyView Investment Advisors first reported a position in JSPRW in Q4 2021 and held it in 6 quarters. The position peaked at $0 in Q1 2023. 10 funds tracked by Wall St. Rank hold JSPRW as of Q2 2023.

  • SkyView Investment Advisors reported no remaining Japer Therapeutics Warrants position as of Q2 2023 after selling out during the quarter.
  • SkyView Investment Advisors sold 302 Japer Therapeutics Warrants shares in Q2 2023.
  • SkyView Investment Advisors first reported a position in Japer Therapeutics Warrants in Q4 2021 and held it in 6 quarters.
  • SkyView Investment Advisors's Japer Therapeutics Warrants position peaked at $0 in Q1 2023.
  • 10 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q2 2023.

Based on SkyView Investment Advisors's 13F filing for Q2 2023, filed 15 Aug 2023.